R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer - PubMed (original) (raw)
. 2010 Feb 15;70(4):1544-54.
doi: 10.1158/0008-5472.CAN-09-2997. Epub 2010 Feb 9.
Alison Pan, Christian Franci, Yuanming Hu, Betty Chang, Weiqun Li, Matt Duan, Allan Torneros, Jiaxin Yu, Thilo J Heckrodt, Jing Zhang, Pingyu Ding, Ayodele Apatira, Joanne Chua, Ralf Brandt, Polly Pine, Dane Goff, Rajinder Singh, Donald G Payan, Yasumichi Hitoshi
Affiliations
- PMID: 20145120
- DOI: 10.1158/0008-5472.CAN-09-2997
R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer
Sacha J Holland et al. Cancer Res. 2010.
Abstract
Accumulating evidence suggests important roles for the receptor tyrosine kinase Axl in cancer progression, invasion, metastasis, drug resistance, and patient mortality, highlighting Axl as an attractive target for therapeutic development. We have generated and characterized a potent and selective small-molecule inhibitor, R428, that blocks the catalytic and procancerous activities of Axl. R428 inhibits Axl with low nanomolar activity and blocked Axl-dependent events, including Akt phosphorylation, breast cancer cell invasion, and proinflammatory cytokine production. Pharmacologic investigations revealed favorable exposure after oral administration such that R428-treated tumors displayed a dose-dependent reduction in expression of the cytokine granulocyte macrophage colony-stimulating factor and the epithelial-mesenchymal transition transcriptional regulator Snail. In support of an earlier study, R428 inhibited angiogenesis in corneal micropocket and tumor models. R428 administration reduced metastatic burden and extended survival in MDA-MB-231 intracardiac and 4T1 orthotopic (median survival, >80 days compared with 52 days; P < 0.05) mouse models of breast cancer metastasis. Additionally, R428 synergized with cisplatin to enhance suppression of liver micrometastasis. Our results show that Axl signaling regulates breast cancer metastasis at multiple levels in tumor cells and tumor stromal cells and that selective Axl blockade confers therapeutic value in prolonging survival of animals bearing metastatic tumors.
Similar articles
- Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma.
Woo SM, Min KJ, Seo SU, Kim S, Kubatka P, Park JW, Kwon TK. Woo SM, et al. Int J Mol Sci. 2019 Jul 2;20(13):3253. doi: 10.3390/ijms20133253. Int J Mol Sci. 2019. PMID: 31269715 Free PMC article. - Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
Tian M, Chen XS, Li LY, Wu HZ, Zeng D, Wang XL, Zhang Y, Xiao SS, Cheng Y. Tian M, et al. Acta Pharmacol Sin. 2021 Jul;42(7):1180-1189. doi: 10.1038/s41401-020-00546-8. Epub 2020 Nov 4. Acta Pharmacol Sin. 2021. PMID: 33149145 Free PMC article. - Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.
Wang C, Jin H, Wang N, Fan S, Wang Y, Zhang Y, Wei L, Tao X, Gu D, Zhao F, Fang J, Yao M, Qin W. Wang C, et al. Theranostics. 2016 May 24;6(8):1205-19. doi: 10.7150/thno.15083. eCollection 2016. Theranostics. 2016. PMID: 27279912 Free PMC article. - Axl inhibitors as novel cancer therapeutic agents.
Shen Y, Chen X, He J, Liao D, Zu X. Shen Y, et al. Life Sci. 2018 Apr 1;198:99-111. doi: 10.1016/j.lfs.2018.02.033. Epub 2018 Feb 27. Life Sci. 2018. PMID: 29496493 Review. - AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations.
Falcone I, Conciatori F, Bazzichetto C, Bria E, Carbognin L, Malaguti P, Ferretti G, Cognetti F, Milella M, Ciuffreda L. Falcone I, et al. Int J Mol Sci. 2020 Nov 10;21(22):8419. doi: 10.3390/ijms21228419. Int J Mol Sci. 2020. PMID: 33182542 Free PMC article. Review.
Cited by
- Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.
Zhang X, Maity TK, Ross KE, Qi Y, Cultraro CM, Bahta M, Pitts S, Keswani M, Gao S, Nguyen KDP, Cowart J, Kirkali F, Wu C, Guha U. Zhang X, et al. Cancer Res. 2021 Jun 1;81(11):3051-3066. doi: 10.1158/0008-5472.CAN-20-2435. Epub 2021 Mar 16. Cancer Res. 2021. PMID: 33727228 Free PMC article. - Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours.
Dave F, Herrera K, Lockley A, van de Weijer LL, Henderson S, Sofela AA, Hook L, Adams CL, Ercolano E, Hilton DA, Maze EA, Kurian KM, Ammoun S, Hanemann CO. Dave F, et al. Oncogene. 2024 Oct;43(41):3049-3061. doi: 10.1038/s41388-024-03131-z. Epub 2024 Aug 23. Oncogene. 2024. PMID: 39179860 Free PMC article. - Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction.
Clemons NJ, Phillips WA, Lord RV. Clemons NJ, et al. Cancer Biol Ther. 2013 Sep;14(9):782-95. doi: 10.4161/cbt.25362. Epub 2013 Jun 17. Cancer Biol Ther. 2013. PMID: 23792587 Free PMC article. Review. - Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC).
Yang PW, Liu YC, Chang YH, Lin CC, Huang PM, Hua KT, Lee JM, Hsieh MS. Yang PW, et al. Front Oncol. 2019 Nov 6;9:1138. doi: 10.3389/fonc.2019.01138. eCollection 2019. Front Oncol. 2019. PMID: 31781483 Free PMC article. - MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK, Cummings CT, Iida M, Hülse J, Pearson HE, Vasileiadi E, Parker RE, Orbuch RA, Ondracek OJ, Welke NB, Kang GH, Davies KD, Wang X, Frye SV, Earp HS, Harari PM, Kimple RJ, DeRyckere D, Graham DK, Wheeler DL. McDaniel NK, et al. Mol Cancer Ther. 2018 Nov;17(11):2297-2308. doi: 10.1158/1535-7163.MCT-17-1239. Epub 2018 Aug 9. Mol Cancer Ther. 2018. PMID: 30093568 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous